

## Table of contents

<b>1</b>	<b>Introduction</b>	<b>4</b>
1.1	Why a study on success rates of biotech companies?	4
1.2	What are success rates?	4
1.3	The role of success rates	5
1.4	Are success rates of biotech companies different?	5
<b>2</b>	<b>Methods</b>	<b>7</b>
2.1	Origin of Data	7
2.2	Difference between FDA and EMEA	7
2.3	Time frame	7
2.4	Success rates per molecule vs. success rates per indication	8
2.5	When does a project count as a success?	8
2.6	Companies of the sample	8
<b>3</b>	<b>Results</b>	<b>11</b>
3.1	Reporting of success and failure	11
3.2	Distribution of sample over disease groups	11
3.3	Overall biotech success rates (IND to approval)	12
3.4	Disease group specific overall success rates (IND to approval)	13
3.5	Number of projects in different disease groups	14
3.6	Approvals by EMEA and FDA	14
3.7	Disease group specific Success Rates	15
3.7.1	Cancer (481 projects)	15
3.7.2	Neurology	16
3.7.3	Infectious (131 projects)	17
3.7.4	Inflammation (148 projects)	17
3.7.5	Cardiovascular (76 projects)	18
3.7.6	Autoimmune (42 projects)	19
3.7.7	Hematology (30 projects)	20
3.7.8	Dermatology (27 projects)	20
3.7.9	Endocrinology (49 projects)	21
3.7.10	Metabolic (71 projects)	21
3.7.11	Genitourinary (30 projects)	22
3.7.12	Musculoskeletal (29 projects)	23
3.7.13	Gastrointestinal (22 projects)	24
<b>4</b>	<b>Discussion</b>	<b>25</b>
4.1	Success Rates in Biotech (Avance) and Pharma (Kola, Landis)	25
4.2	Difference in cancer	30
4.3	Difference in Neurology	31
4.4	Difference in Infectious Diseases	32
4.5	Difference in Inflammation	33
4.6	Difference in Cardiovascular	34
4.7	Biotech has more late stage failures	34
4.8	Case Study: Arpida	36
4.9	Biotech does not abandon low potential drugs	37
<b>5</b>	<b>Conclusion</b>	<b>38</b>

## List of figures & tables

Figure 1: Spreading of projects on different disease groups	11
Figure 2: Overall success rates phase 1 to approval (disease group unspecific)	13
Figure 3: Success rates Phase I to Approval per disease group	14
Figure 4: Success rates FDA vs EMEA	15
Figure 5: Success rates in Cancer	16
Figure 6: Success rates in Neurology	16
Figure 7: Success rates in Infectious disease	17
Figure 8: Success rates in Inflammation	18
Figure 9: Success rates in Cardiovascular	18
Figure 10: Success rates in Autoimmune	19
Figure 11: Success rates in Hematology	20
Figure 12: Success rates in Dermatology	20
Figure 13: Success rates in Endocrinology	21
Figure 14: Success rates in Metabolic disease	22
Figure 15: Success rates in Genitourinary disease	22
Figure 16: Success rates in Musculoskeletal	23
Figure 17: Success rate in Gastrointestinal	24
Figure 18: Overall success rate of all clinical projects over all disease groups	26
Figure 19: Success rate by phase of development and overall therapeutic areas	27
Figure 20: Probability to reach market for biotech and Pharma (Kola Landis)	27
Figure 21: DiMasi Overall disease groups compared to Kola and Avance	29
Figure 22: Success rates Cancer; Kola – Avance	30
Figure 23: DiMasi Cancer compared to Kola and Avance	31
Figure 24: Success rates Neurology; Kola – Avance	32
Figure 25: Success rates Infectious, Kola – Avance	32
Figure 26: Success rates Inflammation, Kola – Avance	33
Figure 27: Success rates Cardiovascular, Kola - Avance	34
Table 1: List of reviewed biotech companies (publicly traded)	10
Table 2: Projects in different disease groups and their overall success rates	12
Table 3: Average clinical R&D spendings for one drug for biotech and Pharma	28
Table 4: Capitalized costs per commercialized drug	29